Delivery Order 36F79724D0176-36C25926F0068
Award Date 12/16/25
Potential Completion Date 1/16/26
Potential Value $352K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Horsham, PA 19044, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., was awarded a firm fixed-price delivery order valued at $18,803.91 by Veterans Integrated Service Network 5 (VISN 5) on August 6, 2025, with an ultimate completion date of August 7, 2025. The contract covers the delivery of BALVERSA (erdafitinib), a specialized oncology medication, to the Veterans Health Administration facility in Carrollton, Texas. This delivery order carries no set-aside designation and is issued under the...
- This federal contract award to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., is for the supply of PHARMACY DRUGS, specifically oncology medications and other specialty drugs, to the U.S. Department of Veterans Affairs (VA). The $356,183.07 ceiling value contract was awarded on October 1, 2023 and has an ultimate completion date of September 30, 2024. This contract is a Delivery Order issued under Janssen Biotech's $3.1 billion multiple-award Federal Supply Schedule (FSS)...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the pharmaceutical product BALVERSA 4MG TABS. The $17,642.95 order was issued against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS) contract (FSS-61-IB) and has a completion date of June 30, 2024. Janssen Biotech Inc. is a for-profit manufacturer of specialty medications, including...
- Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., has been awarded a $17,642.95 firm fixed price delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 to provide BALVERSA 4 MG. The delivery order was placed against Janssen's multiple award GSA Schedule Pharmaceuticals and Drugs contract, also known as FSS-61-IB, which has no set-aside designation and expires in March 2024. As a manufacturer of pharmaceutical...
- Janssen Biotech Inc., a Johnson & Johnson subsidiary operating as Centocor Ortho Biotech Inc., was awarded a delivery order valued at $18,803.91 for BALVERSA 4 MG (erdafitinib), an oncology medication, by Veterans Integrated Service Network 5 (VISN 5) under the Department of Veterans Affairs. The firm fixed-price delivery order was awarded on September 25, 2025, with an ultimate completion date of September 29, 2025, and will be performed in Carrollton, Texas. This award carries no set-aside...
- Janssen Biotech, Inc. was awarded a $15,754.46 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract vehicle by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5. The firm fixed price order is for the drug BALVERSA 4MG and has a period of performance through December 7, 2022. No set-aside provisions were applied to this award to supply prescription medications in support of healthcare...
- Janssen Biotech, Inc. was awarded a $17,046.33 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract vehicle by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 10. The firm fixed price order is for the drug BALVERSA 4MG and has a period of performance through May 12, 2023. No set-aside provisions were applied to this order. The Veterans Health Administration procures pharmaceuticals through...
- Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., has been awarded a $17,642.95 firm fixed price delivery order for BALVERSA 4MG tablets from the Department of Veterans Affairs Veterans Health Administration (VHA) under the company's Pharmaceuticals and Drugs (FSS-61-IB) multiple award schedule contract. The delivery order, which has no set-aside designation and expires March 31, 2024, will provide cancer treatment medications to the VHA's Veterans Integrated Service Network...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) has awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., to provide the chemotherapy drug BALVERSA (erdafitinib) for patient care. The $17,642.94 delivery order was issued against Janssen's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has a period of performance through May 7, 2024 and was awarded on May 2,...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) has awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the supply of the chemotherapy drug BALVERSA (erdafitinib). This order is issued against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a $3.1 billion multiple award schedule that allows VHA to procure prescription drugs. The potential value of this specific...